{"id":15527,"date":"2023-12-18T19:33:20","date_gmt":"2023-12-18T14:03:20","guid":{"rendered":"https:\/\/www.fitterfly.com\/blog\/?p=15527"},"modified":"2024-02-20T13:47:12","modified_gmt":"2024-02-20T08:17:12","slug":"technology-revolution-redefining-the-diabetes-care-experience","status":"publish","type":"post","link":"https:\/\/www.fitterfly.com\/blog\/technology-revolution-redefining-the-diabetes-care-experience\/","title":{"rendered":"Technology Revolution Redefining the Diabetes Care Experience"},"content":{"rendered":"<h2><b>Abstract:<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Tech-driven revolution through continuous glucose monitoring, closed-loop insulin delivery, AI-powered chatbots and virtual clinics are redefining the future of diabetes management. Though physicians and patients exhibit mixed perspectives on diabetes technology, it can reduce the global diabetes burden considerably. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Research studies will overcome its present challenges like data security, privacy concerns, cyber threats, and standardisation in technologies and protocols.<\/span><\/p>\n<h2><b>Diabetes Technology Leading a Paradigm Shift in Treatment Process<\/b><\/h2>\n<p>Diabetes technology<span style=\"font-weight: 400;\"> is spearheading a transformative paradigm shift in treatment processes over the past few decades. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Innovative technologies in diabetes care offer continuous glucose monitoring, and improved patient self-care through empowerment, glycemic control optimisation, behaviour modifications and precise insulin delivery. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">The escalating global burden of diabetes is driving scientists to develop state-of-the-art technologies to revolutionise diabetes care and enhance patients\u2019 lives.<\/span><\/p>\n<h2><b>Physicians&#8217; and Patients\u2019 Perspectives on Diabetes Technology<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Clinicians and patients have mixed views regarding the use of <\/span>diabetes technology<span style=\"font-weight: 400;\">, as per an analysis encompassing <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32804989\/\"><span style=\"font-weight: 400;\">13 articles and 242 patients, (age 18-81 years<\/span><\/a><span style=\"font-weight: 400;\">). <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Though the integration of technologies does not have any direct impact on diabetes distress scores,<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6351708\/\"><span style=\"font-weight: 400;\"> studies<\/span><\/a><span style=\"font-weight: 400;\"> have revealed that there is a notable reduction in diabetes burden and improvement in quality of life when patients rely on technologies.<\/span><\/p>\n<p><span style=\"font-weight: 400;\"> People living with diabetes become increasingly adherent to technology if they are seamless to access, implement and provide reliable information.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Physicians&#8217; primary concerns related to implementing diabetes technology include costs, achieving adherence and attaining learning curves. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">A study involving 209 clinicians highlights a generational divide, where <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5505431\/\"><span style=\"font-weight: 400;\">younger health professionals harboured more positive attitudes regarding the use of diabetes technologies<\/span><\/a><span style=\"font-weight: 400;\"> than senior doctors. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">However, higher expenditures and lack of healthcare system coverage are major barriers for doctors and patients in implementing diabetes technology.<\/span><\/p>\n<h2><b>Latest Innovations in Diabetes Technology<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Technological solutions in diabetes management provide safety, support, and self-efficacy for achieving a good glycaemic legacy and preventing complications. They target to reduce the diabetes burden by providing real-time information facilitating decisions.<\/span><\/p>\n<p><span style=\"font-weight: 400;\"> The following are some of the latest diabetes technologies in use today.<\/span><\/p>\n<h3><b>1. Continuous Glucose Monitoring<\/b><\/h3>\n<p>Continuous glucose monitoring (CGM) devices<span style=\"font-weight: 400;\"> help in determining the blood sugar of individuals at regular intervals painlessly. CGM devices are of two types- intermittently viewed CGM (iCGM) and real-time CGM (rtCGM) gadgets. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">The former offers glycaemic information on demand retrospectively, while the latter provides real-time data. rtCGM integrated insulin pump also enables timely insulin infusion based on real-time glycaemic values.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Fitterfly\u2019s 90 days R<\/span><a href=\"https:\/\/diabetes.jmir.org\/2023\/1\/e43292\"><span style=\"font-weight: 400;\">eal-world Effectiveness Evaluation of its Diabetes CGM DTx Program<\/span><\/a><span style=\"font-weight: 400;\"> published on JMIR Diabetes (2023;8:e43292) achieved the following results:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A 1.2% decrease in HbA1C levels among 85% of the participants.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">An average reduction of 2.6% in HbA1C levels for those with initial HbA1c levels &gt;9%.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A significant correlation between high engagement with the Fitterfly wellness app and weight reduction in participants.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Time in Range (TIR) improved by 7.1% from a baseline value of 57.5% to 64.6%.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Time above Range (TAR) was reduced by 8.7% from a baseline value of 36.7% to 28.1%.\u00a0<\/span><\/li>\n<\/ul>\n<p><img decoding=\"async\" class=\"alignnone wp-image-15528 size-full lazyload\" data-src=\"https:\/\/www.fitterfly.com\/blog\/wp-content\/uploads\/2023\/12\/Has-technology-changed-diabetes-management-2.jpg\" alt=\"Changes in CGM Metrics among participants of the Fitterfly Diabetes CGM DTx Program.\" width=\"1200\" height=\"628\" data-srcset=\"https:\/\/www.fitterfly.com\/blog\/wp-content\/uploads\/2023\/12\/Has-technology-changed-diabetes-management-2.jpg 1200w, https:\/\/www.fitterfly.com\/blog\/wp-content\/uploads\/2023\/12\/Has-technology-changed-diabetes-management-2-300x157.jpg 300w, https:\/\/www.fitterfly.com\/blog\/wp-content\/uploads\/2023\/12\/Has-technology-changed-diabetes-management-2-1024x536.jpg 1024w, https:\/\/www.fitterfly.com\/blog\/wp-content\/uploads\/2023\/12\/Has-technology-changed-diabetes-management-2-768x402.jpg 768w\" data-sizes=\"(max-width: 1200px) 100vw, 1200px\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" style=\"--smush-placeholder-width: 1200px; --smush-placeholder-aspect-ratio: 1200\/628;\" \/><noscript><img decoding=\"async\" class=\"alignnone wp-image-15528 size-full\" src=\"https:\/\/www.fitterfly.com\/blog\/wp-content\/uploads\/2023\/12\/Has-technology-changed-diabetes-management-2.jpg\" alt=\"Changes in CGM Metrics among participants of the Fitterfly Diabetes CGM DTx Program.\" width=\"1200\" height=\"628\" srcset=\"https:\/\/www.fitterfly.com\/blog\/wp-content\/uploads\/2023\/12\/Has-technology-changed-diabetes-management-2.jpg 1200w, https:\/\/www.fitterfly.com\/blog\/wp-content\/uploads\/2023\/12\/Has-technology-changed-diabetes-management-2-300x157.jpg 300w, https:\/\/www.fitterfly.com\/blog\/wp-content\/uploads\/2023\/12\/Has-technology-changed-diabetes-management-2-1024x536.jpg 1024w, https:\/\/www.fitterfly.com\/blog\/wp-content\/uploads\/2023\/12\/Has-technology-changed-diabetes-management-2-768x402.jpg 768w\" sizes=\"(max-width: 1200px) 100vw, 1200px\" \/><\/noscript><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 10pt;\"><i><span style=\"font-weight: 400;\">Fig: Changes in CGM Metrics among participants of the Fitterfly Diabetes CGM DTx Program.<\/span><\/i><\/span><\/p>\n<p><span style=\"font-weight: 400;\">Now scientists have also developed <\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26177299\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">long-term implantable subcutaneous fluorescence-based CGM sensors <\/span><\/a><span style=\"font-weight: 400;\">which can remain active for up to 180\u2009days. Researchers are further working to extend this duration.<\/span><span style=\"font-weight: 400;\">\u00a0<\/span><\/p>\n<h3><b>2. Continuous Ketone Monitoring (CKM) by Ketone Sensors<\/b><\/h3>\n<p>Diabetes patients tend to develop higher levels of ketones in blood circulation, thereby increasing the release of counter-regulatory hormones, like glucagon. The hormone imbalances may lower the blood pH and can cause severe organ damage or even death.<br \/>\n<b><\/b><\/p>\n<p><span style=\"font-weight: 400;\">Continuous ketone sensors significantly improve patients\u2019 outcomes by continuously calculating the ketone in blood circulation. They determine beta-hydroxybutyrate (BHB) in interstitial fluid (ISF) based on wired enzyme electrochemistry technology.<\/span><\/p>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8258504\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Jennifer Y. Zhang et al conducted a 14-day ketone sensor study on 12 human volunteers<\/span><\/a><span style=\"font-weight: 400;\">. The gadget\u2019s operational stability was significantly accurate with a linear response over the 0-8\u2009mM range.<\/span><\/p>\n<p><span style=\"font-weight: 400;\"> Research is going on for a possible integration of CKM and CGM devices on the same sensor platform.\u00a0<\/span><\/p>\n<h3><b>3. Insulin Pumps and Closed Loop Delivery Systems<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Continuous subcutaneous insulin infusion (CSII) with the help of <\/span>insulin pumps<span style=\"font-weight: 400;\"> is a well-established therapeutic option, especially for managing T1DM. Though the first CSII pump came into service in 1979, present-day pumps come with a bolus calculator and automatic basal rate suspension to reduce hypoglycaemia.<\/span><\/p>\n<p><span style=\"font-weight: 400;\"> A <\/span><a href=\"https:\/\/diabetesjournals.org\/care\/article\/26\/4\/1079\/23670\/Insulin-Pump-TherapyA-meta-analysis\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">meta-analysis undertaken in 2003, involving 52 studies and 1547 participants<\/span><\/a><span style=\"font-weight: 400;\"> indicated that there was a\u00a0 0.8-1% drop in HbA1c level and mean blood glucose levels (in 11 studies) among members with CSII.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Currently, scientists are working towards subcutaneous closed-loop system development. These devices will fully automate all insulin delivery without any mealtime bolus inputs from users. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">However, the primary challenge of a closed-loop system is postprandial hyperglycemia management, as there is no manually provided information related to the meal\u2019s carbohydrate content and timings. Presently, <\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9207329\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">STG-55 (Nikkiso, Tokyo, Japan) and its predecessor, the STG-22<\/span><\/a><span style=\"font-weight: 400;\"> are the only commercially available fully closed-loop insulin pumps.\u00a0<\/span><\/p>\n<h3><b>4. Chatbots<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Artificial intelligence (AI), natural language processing (NLP), and machine learning (ML)-driven healthcare chatbots interact with patients, analyse their queries and provide logical answers. Patients consider chatbots superior to other Diabetes Self-Management Education and Support (DSME) devices as they come with human-like characteristics.<\/span><\/p>\n<p><span style=\"font-weight: 400;\"> Patients achieve higher levels of engagement and are more likely to become adherent to their treatment plans upon receiving consistent reminders and personalised guidance from AI chatbots. <\/span><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s44163-021-00005-1#:~:text=AIDA%20Chatbot%E2%80%94the%20text%2Dbased,with%20a%20diabetic%20patient's%20diet.\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Artificial Intelligence Diabetes Assistant (AIDA)<\/span><\/a><span style=\"font-weight: 400;\">, Chatgpt, <\/span><a href=\"https:\/\/advanced-hindsight.com\/wp-content\/uploads\/2018\/02\/Chatbots-for-Diabetes-Self-Management.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Emile, X2AI<\/span><\/a><span style=\"font-weight: 400;\">, and JEDi are some popular diabetes care chatbots.<\/span><\/p>\n<h3><b>5. Smartphone Apps, Telemedicine and Virtual Clinics<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">Diabetes self-management often becomes challenging due to a lack of training, limited access to medical professionals, and hurdles in behavioural modifications. Smartphone <\/span>diabetes apps <span style=\"font-weight: 400;\">available on Google Play and Apple App Store are found to deliver encouraging results in initiating sustaining behaviour changes and improving patients\u2019 compliance. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Similarly, telemedicine and virtual diabetes clinics have shown promising results in removing geographical barriers, reducing treatment costs, and improving patient access to health care and clinical outcomes.<\/span><\/p>\n<h2><b>Challenges in Integrating Technology in Diabetes Care<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Though there is great enthusiasm among both healthcare professionals and patients in implementing diabetes technology, here are a few challenges associated to it:<\/span><\/p>\n<h3><b>1. Data Security and Privacy Concerns<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">The collection and storage of patients\u2019 vital information is a critical issue. Health tech companies are working towards minimising cyber threats and data breaches. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Regulatory bodies like the <\/span><a href=\"https:\/\/diabetesjournals.org\/care\/article\/43\/1\/250\/35864\/Diabetes-Digital-App-Technology-Benefits\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">American Diabetes Association (ADA), the European Medicines Agency (EMA), and the European Association for the Study of Diabetes (EASD)<\/span><\/a><span style=\"font-weight: 400;\"> have enforced strict guidelines so that patient safety and clinical validity never get compromised.<\/span><\/p>\n<h3><b>2. Standardization of Technologies and Protocols<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">The diversity of devices, data formats, and communication protocols often leads to a lack of standardisation in technologies and protocols. These hurdles make it challenging to establish a universal standard for diabetes management technology.<\/span><\/p>\n<p><span style=\"font-weight: 400;\"> Standardization would facilitate the seamless exchange of information between different systems and promote interoperability.\u00a0<\/span><\/p>\n<h3><b>3. Cost and Accessibility<\/b><\/h3>\n<p><span style=\"font-weight: 400;\">The financial aspect of integrating technology into diabetes care is a significant hurdle. Most state-of-the-art technologies and devices come with a high implementation cost, thus making them inaccessible to a large magnitude of diabetic patients.<\/span><\/p>\n<p><span style=\"font-weight: 400;\"> Scientists are working towards developing new technologies which can bring down this cost.<\/span><\/p>\n<h2><b>Summarising the Impact of Diabetes Technology on Patient Outcomes<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">Finally, we can say that the integration of <\/span>technology in diabetes<span style=\"font-weight: 400;\"> care marks a transformative shift. The latest innovations, ranging from CGM devices to advanced chatbots and closed-loop insulin delivery systems, hold the promise of empowering patients, optimising glycemic control, and preventing complications. <\/span><\/p>\n<p><span style=\"font-weight: 400;\">Since the global burden of diabetes is increasing exponentially, technological integration remains a beacon of hope. By overcoming its challenges and embracing the potential of innovative solutions, the future of diabetes care holds the promise of improved patient outcomes.<\/span><\/p>\n<h2><b>Key Takeaways:<\/b><\/h2>\n<p><span style=\"font-weight: 400;\">The blog highlights the impact of the latest diabetes technology in streamlining treatment. Here are the key takeaways:<\/span><\/p>\n<ol>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The integration of <\/span>technology in diabetes<span style=\"font-weight: 400;\"> care empowers patients, optimises glycemic control, and holds the potential to prevent complications.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The perspectives of physicians and patients reflect a dynamic landscape. Patients\u2019 adherence is influenced by factors such as seamless access, ease of implementation, and the provision of reliable information.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">CGM devices, ketone sensors, insulin pumps, chatbots, smartphone apps and telemedicine are some of the latest innovations in diabetes technology.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Data security, privacy concerns, cyber threats, standardisation in technologies and protocols, and cost factors are some of the primary challenges in diabetes technology.<\/span><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Explore the impact of diabetes technology on patient outcomes. From CGM to closed-loop insulin delivery &#038; chatbots, witness the paradigm shift in treatment.<\/p>\n","protected":false},"author":40,"featured_media":15529,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"wds_primary_category":1,"footnotes":""},"categories":[418,1,413],"tags":[],"acf":{"reviewed_by":false,"references":null,"author":"","table_content":null,"medically_reviewed":15514,"show_updated_date_in_post":"No","faq_list":null,"custom_schema":"","media_url":"","reviewer":null},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.fitterfly.com\/blog\/wp-json\/wp\/v2\/posts\/15527"}],"collection":[{"href":"https:\/\/www.fitterfly.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fitterfly.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fitterfly.com\/blog\/wp-json\/wp\/v2\/users\/40"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fitterfly.com\/blog\/wp-json\/wp\/v2\/comments?post=15527"}],"version-history":[{"count":0,"href":"https:\/\/www.fitterfly.com\/blog\/wp-json\/wp\/v2\/posts\/15527\/revisions"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.fitterfly.com\/blog\/wp-json\/wp\/v2\/reviewers\/15514"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fitterfly.com\/blog\/wp-json\/wp\/v2\/media\/15529"}],"wp:attachment":[{"href":"https:\/\/www.fitterfly.com\/blog\/wp-json\/wp\/v2\/media?parent=15527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fitterfly.com\/blog\/wp-json\/wp\/v2\/categories?post=15527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fitterfly.com\/blog\/wp-json\/wp\/v2\/tags?post=15527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}